The SMC Group and EMCVPA Partner to Boost Jamaica’s Creative Industries
30.6.2021 17:00:00 EEST | Business Wire | Press release
Jamaica’s creative sector has received a major boost through a partnership between global entertainment marketing agency, The SMC Group, and The Edna Manley College of the Visual and Performing Arts (EMCVPA). This arrangement aims to foster the development of Jamaican talent and the island’s Creative Industries.
The venture will begin with an investment into the development of a music production studio to support local song writers, producers, and artistes. SMC also intends to recruit EMCVPA students for apprenticeships and job placements. This ground-breaking initiative will enhance the music and audio production, animation, as well as dance specialisations at the College.
The partnership is the latest positive development in the island’s creative industries which have seen considerable growth in recent years.
In the film industry, more than 4000 film-related jobs have been created in the last three years while approximately 150 foreign productions are facilitated per year. Over 3 billion JMD in film production expenditure was contributed to GDP in the last two years, and approximately 65-70 percent of crews hired on most international film productions in Jamaica are local.
The country also has a growing animation industry with 15 local studios having participated in government-led programmes to increase their profitability and sustainability.
CEO of The SMC Group, Maurice Hamilton, revealed that the collaboration between the group and EMCVPA will add to the progress that has already been made in the creative industries by expanding investment into the areas of talent and content in the music and audio-visual sectors.
“This is the first step of an exciting initiative to establish Jamaica and then the wider Caribbean region as a creative hub that will develop creative and business professionals as well as content,” the CEO remarked. “And for SMC, it creates a solid, efficient pipeline of creative talent to service our global clients.”
The CEO also disclosed that SMC intends to build a centre of excellence in Jamaica and will be engaging in additional investments and local partnerships.
“We want to ensure that our commitment to Jamaican talent is substantive,” he insisted. “Through greater education, funding, and through our network within the global marketplace we can provide a platform from which Jamaican talent can flourish internationally.”
The island has seen several ventures over the years led by the private sector, public sector or both, which seek to advance the creative industry. Programmes such as the Business of Sustainability for Studios (BOSS) programme, JAFTA Propella film development programme, and the Film Lab initiative help entrepreneurs grow their animation and film production studios, and increase content development.
In the spirit of these collaborations between industry stakeholders, Diane Edwards, President of Jamaica’s investment and export promotions agency, JAMPRO, welcomed the cooperation between SMC and EMCVPA.
“At JAMPRO, we believe that partnership is essential to building local industries and to creating valuable opportunities for Jamaica’s people, so we are pleased to see this agreement between SMC and Edna Manley College,” she said.
EMCVPA’s Vice Principal of Administration and Resource Development, Ms. Kerry Ann Henry, shared her enthusiasm for the partnership and explained that its objectives were in keeping with the college’s mission. She stated, “This is a partnership that will not just strengthen our respective organizations, it will be of enormous benefit to the country in fields related to the visual and performing arts.”
About The SMC Group
The SMC Group operates in 17 markets across the globe and has worked on campaigns for brands like The Coca-Cola Company, Net-A-Porter, Unilever, Diageo, Cartier and a host of globally recognizable names. Their projects have also involved celebrities like Jamaican Olympian Usain Bolt, Korean pop band BTS, Colombian superstar Maluma and American celebrities such as Kevin Hart, Jason Derulo and Kanye West.
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/.
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005271/en/
Contact information
Integrated Marketing Communications
Tamica Parchment
tparchment@jamprocorp.com
Tele: 876-978-7755
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
